Sanofi acquires immune and inflammatory disease specialist Kymab
Sanofi has acquired Kymab, a clinical-stage biopharmaceutical company based in Cambridge, developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology...
Merger Agreement for Astellas Pharma Inc and iota Biosciences
Astellas Pharma Inc. and iota Biosciences, Inc. have announced that Astellas, through a U.S. subsidiary, and iota have entered into a Merger Agreement, with...
Merger announced between RBW Consulting and Thorp Associates, with new Chief Growth Officer
A merger has been announced between RBW Consulting, specialist life science and technology search consultancy, and Thorp Associates, executive search and selection company. Emma Thorp,...
AbbVie to acquire Allergan in “transformative move”
Abbvie to acquire Allergan after entering into a definitive transaction agreement under which AbbVie will acquire the company in a cash and stock transaction...
Novartis acquires IFM Tre
Novartis will add to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC focused...
GHO Capital acquires Sterling Pharma Solutions
European specialist investor in healthcare, GHO Capital, has acquired a majority stake in Sterling Pharma Solutions, a specialist in complex and difficult to manufacture...
Healthtech M&A and IPO Activity
The latest Healthtech M&A and IPO Activity Market Report from Hampleton Partners has revealed a final count of almost 100 deals in the healthtech...
DoseCare acquires Biodose
DoseCare announces its acquisition of Biodose, the UK’s only monitored dosage system (MDS) that accommodates liquid and solid medication. Biodose, a medication management solution,...
UK pharma pressing ahead with M&As in 2019
The UK pharmaceutical industry is pressing ahead with M&A activity and is geared to weather any disruption due to Brexit, according to the results...
Sanofi and Denali join forces on inflammatory disease drugs
Sanofi plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to be neurological and systemic inflammatory disease...
Latest articles
Antibiotic Research UK launches small research grants programme
Antibiotic Research UK (ANTRUK), the world’s first charity tackling bacterial antibiotic resistance, has just launched its largest grants programme to date, the 2021 Small...
First AI-designed Immuno-Oncology drug to enter clinical trials
Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...
The first self-administered B-cell therapy for patients with relapsing forms of MS
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
The first self-administered B-cell therapy for patients with relapsing forms of MS
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
New COVID-19 test reduces testing time from 30 minutes to five
University of Birmingham researchers have invented a COVID-19 test that reduces testing time from 30 minutes to under five, whilst still delivering accurate results. The...
First AI-designed Immuno-Oncology drug to enter clinical trials
Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...